Finland· FI-REL-REL11845

Vioxx

A rofecoxib product containing rofecoxib, registered in Finland by Merck Sharp & Dohme B.V.. The same ATC class is registered in 2 of our 19 countries.

ATC M01AH02

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedVioxxATCM01AH02REGISTER NO.FI-REL-REL11845PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Rofecoxib is registered in 2 of 19 countries.

Countries holding a registration under ATC M01AH02 (rofecoxib), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 1 of them publish a price we can compare per daily dose

Rofecoxib · ATC M01AH02

2 / 19 countries

  • Finlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Active substance
Rofecoxib
Manufacturer
Merck Sharp & Dohme B.V.
Country
Finland (FI)
ATC code
M01AH02
ATC class
Rofecoxib
Defined daily dose
25 mg, O
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

327 interactions on record for rofecoxib.

Graded by severity as the source publishes them — 20 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Rofecoxib · interactions on record

327 records

  • 20 severe
  • 122 moderate
  • 185 info

Most severe, free to view

  • TemsirolimusL01EG01severe
  • EverolimusL01EG02severe
  • SirolimusL01EG04severe
  • TemsirolimusL01XE09severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Rofecoxib in 1 other country

What each register calls a product with the same active substance — salts and hydrates count as the same.

All rofecoxib products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/fbb301e3-d6d8-4b5b-a57c-e10af4d64562
GET /v1/drugs/fbb301e3-d6d8-4b5b-a57c-e10af4d64562?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "25",
  "form": "tabletti",
  "route": null,
  "ddd_unit": "mg",
  "strength": "12.5 mg",
  "atc_label": "rofekoksibi",
  "ma_number": "14467",
  "auth_status": "Myyntilupa peruuntunut",
  "eu_ma_number": null,
  "fimea_rel_id": "REL11845",
  "authorised_at": "1999-10-25"
}

See everything about rofecoxib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.